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Abstract: Strabismus surgery in pediatric patients is associated with a high incidence of 
postoperative nausea and vomiting (PONV). Ondansetron disintegrating tablets (ODT), an oral 
freeze-dried formulation of the 5-HT3 antagonist, are well-tolerated and have been shown to 
reduce chemotherapy-induced vomiting. The purpose of this study was to assess the efﬁ  cacy of 
the ODT in preventing postoperative vomiting (POV) in children undergoing strabismus repair. 
Healthy children aged 4–12 years of age were administered a 4 mg ODT 30 minutes prior to the 
induction of general anesthesia. Induction and maintenance of anesthesia were standardized; 
each child received acetaminophen and ketorolac pre-emptively for analgesia. This study group 
was compared with a historical control group who received a placebo in previously conducted 
identical trials of POV. The 35 children included in this study were compared with 31 controls. 
The incidence and severity of POV and use of rescue antiemetics were signiﬁ  cantly lower in 
children who received ODT compared with placebo (p  0.001). The acute complete response 
(ie, no emesis and no rescue antiemetics in 24 hours) was 76% in the ODT group compared 
with 16% in the controls (p  0.001). Results suggest that ODT given preoperatively reduces 
the incidence and severity of POV in children undergoing strabismus surgery.
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Introduction
The incidence of postoperative nausea and vomiting (PONV) in children varies from 
5% to 80% (Baines 1996). The etiology is complex and multifaceted, including patient-
related factors, type of surgical procedure, choice of anesthetic agents, and postoperative 
management (Sung 1996). Children undergoing strabismus surgery are particularly prone 
to PONV. Postoperative vomiting (emesis) is the forceful expulsion of gastrointestinal 
contents through the mouth (Kovac 2000) and is mediated by a variety of neurotrans-
mitters including serotonin which binds to serotonergic (5-HT3) receptors located both 
peripherally on the vagal nerve terminals and centrally in the chemoreceptor trigger 
zone of the area postrema (Borison 1989). The serotonin receptor antagonists (including 
ondansetron, dolasetron, granisetron, and tropisetron), purportedly block the effects of 
serotonin in the chemoreceptor trigger zone, nucleus tractus solitarius, and vagal afferents 
(Wadibia 1999). These antiemetic agents have been shown to reduce chemotherapy in-
duced nausea and vomiting, as well as PONV. Intravenous (IV) ondansetron administered 
in doses ranging from 40–200 mcg/kg has been extensively studied for prevention of 
PONV in children undergoing strabismus surgery (Bowhay et al 2001).
An innovative freeze-dried ondansetron oral disintegrating tablet (ODT) was 
developed to allow for disintegration on the tongue with dissolution and rapid 
absorption in the gastrointestinal tract in the absence of water (see http://us.gsk.com/). 
The active ingredient in ODT is the racemic form of ondansetron, and a 4-mg ODT 
contains 4 mg of ondansetron base. Davidson and colleagues (1999) have demonstrated Therapeutics and Clinical Risk Management 2007:3(4) 692
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equivalency of ODT 8 mg to oral ondansetron 8 mg in highly 
emetogencic chemotherapy. The pharmacokinetic data sug-
gests that ondansetron is readily and completely absorbed 
from the gastrointestinal tract following oral administration 
(Roila and Del Favero 1995). In children undergoing highly 
emetogenic chemotherapy, ODT (4–8 mg) showed similar 
efﬁ  cacy for complete control of emesis compared with IV 
ondansetron; 93% versus 92% respectively, and was consid-
ered safe, well tolerated and cost effective (Corapcioglu and 
Sarper 2005). In children undergoing adenotonsillectomy, a 
ﬁ  xed dose of 4 mg ODT resulted in the number needed to 
treat (NNT) = 2.86 with a relative risk reduction for PONV 
of 50%. Additionally, the ODT was found to be acceptable 
in taste with 87% of patients willing to take the medication 
in the future (Cohen et al 2005). The properties of ODT make 
it a potentially useful agent in children who cannot swallow 
water or pills during the perioperative period. The purpose of 
this study, therefore, was to determine the efﬁ  cacy of ODT 
in reducing the incidence and severity of POV in children 
undergoing outpatient strabismus surgery.
Methods
Approval from the University of Michigan Institutional Review 
Board (IRB) and written informed consent from a parent or 
legal guardian was obtained for this prospective, observational, 
historically controlled study. Healthy children aged 4–12 years 
of age, ASA I-II, scheduled to undergo strabismus surgery 
were recruited. Those with a history of cardiac, hepatic, renal or 
neurological impairment, prior severe PONV, known sensitivity 
to 5-HT3 receptor antagonists, and requirement for premedication 
were excluded.
Preoperatively, each child received an oral dose of acet-
aminophen (15 mg·kg−1) followed by a 4 mg ODT 30 minutes 
prior to induction of anesthesia. Acceptability of the ODT 
was scored using a 4 point scale (1 = readily, 2 = reluctant, 
3 = held down, 4 = refused). General anesthesia was induced 
with sevoﬂ  urane via facemask. A laryngeal mask airway 
(LMA) was placed and anesthesia was maintained with iso-
ﬂ  urane. Ketorolac (0.5 mg·kg−1) was administered following 
placement of the IV intraoperatively. At the completion of the 
surgery, the stomach was aspirated via an oral-gastric tube 
and the LMA was removed at the discretion of the anesthe-
siologist. Strict adherence to the protocol were maintained 
by research personnel who were present the entire time of 
the surgical procedure.
Postoperatively, children were observed for any episode 
of POV or retching. Two or more episodes of vomiting or 
retching were treated with metoclopramide 0.15 mg·kg−1 IV as 
a rescue medication. Pain was assessed using the Faces, Legs, 
Activity, Cry and Consolability (FLACC) observational pain 
scale and children with scores 4 were treated with morphine 
sulfate 0.05 mg·kg−1 IV titrated per routine practice. Parents 
were telephoned the day after surgery to assess further POV, 
treatment and potential adverse effects. Additionally, parents 
rated their satisfaction with the prevention and treatment of 
POV as 1 = very dissatisﬁ  ed, 2 = dissatisﬁ  ed, 3 = satisﬁ  ed, 
4 = very satisﬁ  ed.
Historical placebo controls from previous studies of 
POV conducted at the same institution using the same 
identical anesthetic technique and research protocol were 
used for statistical comparison (Munro et al 1999; Wagner 
et al 2003). These studies were placebo controlled stud-
ies of POV in children undergoing strabismus surgery. 
Patients were randomized to IV dolasetron in a fixed 
dose and weight based dose versus IV sodium chloride or 
oral granisetron compounded in strawberry syrup versus 
strawberry syrup alone each in equivalent volumes. For the 
purposes of analyses, the severity of POV was classiﬁ  ed 
as mild (1 episode), moderate (2 episodes), or severe (3 or 
more episodes). Additionally, the primary efﬁ  cacy measure 
was an acute complete response (ACR) which was deﬁ  ned 
as no emetic episodes or rescue antiemetic medication use 
within 24 hours of ODT 4 mg administration. Categorical 
data such as ACR, and the incidence and severity of PONV 
were compared using chi-square with Fisher’s exact tests as 
appropriate. Patient age, weight, and other parametric data 
were compared using unpaired t-tests. Data are reported 
as mean + SD or n (%) with p values of <0.05 considered 
statistically signiﬁ  cant. 
Results
A total of 49 children were enrolled in the study. Fourteen 
children were excluded due to protocol violations such as 
administration of morphine intraoperatively or use of addi-
tional prophylactic antiemetics. Data from 35 children who 
received ODT are, therefore, reported. The historical control 
group included 31 children who received placebo in 2 studies 
as described previously (Munro et al 1999; Wagner et al 
2003). The demographics and perioperative data were similar 
between the placebo and ODT groups, with the exception 
that children in the ODT group had a signiﬁ  cantly longer 
anesthetic duration compared with controls (Table 1).
Outcome data including the incidence and severity of 
POV, use of rescue medications, and ACR are presented in 
Table 2. One hundred percent of the patients readily accepted 
the ODT and no children were admitted to the hospital as a Therapeutics and Clinical Risk Management 2007:3(4) 693
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result of POV. Nausea was only assessed in children able to 
verbalize and understand the concept of nausea by a yes/no 
response. The incidence headache, abdominal pain, emer-
gence agitation and other side effects were similar between 
groups. The respective incidences for the ODT compared 
with placebo were 72.7% versus 67.7% for headache, 96.9% 
versus 93.5% for abdominal pain, and 2.9% versus 0.0% for 
emergence delirium 
Discussion
Postoperative nausea and vomiting remain a leading cause 
of morbidity in pediatric surgical patients, contributing to 
bleeding, dehydration, wound dehiscence and the potential for 
pulmonary aspiration (Rose and Watcha 1999). Additionally, 
severe PONV occurs with a frequency of 1%–3% and may 
result in unanticipated hospital admission leading to increased 
institutional costs. A recent multi-center study involving 1257 
children aged birth-14 yrs old showed that strabismus surgery 
was an independent risk factor for postoperative vomiting. Of 
all risk factors it was the most signiﬁ  cant with an OR of 5.2 
similar to other reported incidences of up to 87%. Findings 
from this study demonstrate that prophylactic administration 
of ODT in a ﬁ  xed dose of 4 mg reduced the incidence and 
severity of PONV in young children undergoing strabismus 
surgery (Eberhart et al 2004). Additionally, recent studies sug-
gest that ODT is similarly useful for the prevention of PONV 
in children. Cohen and colleagues (2005) compared 4 mg ODT 
versus placebo in children undergoing adenotonsillectomy. 
Although patients also received intraoperative dexamethasone, 
the ODT group experienced signiﬁ  cantly less vomiting and 
the ODT was readily accepted (Cohen et al 2005). In adult 
patients Gan and colleagues (2002) evaluated the ODT in 
patients undergoing outpatient gynecological laparoscopy 
with general anesthesia. Patients received 4 mg of IV ondan-
setron at induction and either 8 mg ODT or placebo prior to 
discharge. The ODT group experienced less severe nausea 
and fewer episodes of vomiting after discharge from PACU 
compared with the placebo group (Gan et al 2002). A study in 
craniotomy surgery patients also evaluated the postoperative 
administration of the ODT in an 8 mg dose compared with 
placebo as rescue therapy for PONV. Patients who received the 
ODT required less rescue therapy with metoclopramide than 
did the placebo group (Hartsell et al 2005). It appears that the 
ODT formulation may be efﬁ  cacious for both the prevention 
and treatment of PONV in adults and possibly children.
The antiemetic efficacy of ODT has also been 
demonstrated previously for both radio-therapy, and che-
motherapy induced nausea and vomiting (Davidson et al 
1999; LeBourgeois et al 1999). A study in patients receiv-
ing cyclophosphamide chemotherapy compared 8 mg of 
oral ondansetron (OT) to 8 mg of ODT given twice daily 
for 3 days. The ODT was found to be equivalent to the OT 
for control of emesis with 89% of patients ﬁ  nding the taste 
acceptable (Davidson et al 1999).
Although there remains an ongoing debate over the 
appropriate timing of administration of the 5-HT3 antagonists, a 
recent study by Madan and colleagues (2000) found no difference 
in efﬁ  cacy between groups of children who received 0.1 mg/kg 
ondansetron IV at induction versus the end of strabismus surgery. 
It appears that in pediatric strabismus surgery, the time of 
administration of ondansetron is not related to efﬁ  cacy (Madan 
et al 2000). Data suggest that ondansetron is completely and 
readily absorbed from the gastrointestinal tract following oral 
administration (Roila and Del Favero 1995). The time to reach 
peak concentration is between 0.5 to 2 hours with an approximate 
160 liter volume of distribution and 70 to 76% plasma protein 
binding. The elimination half-life averages approximately 3.8 ± 1 
hour and is extensively metabolized primarily through hydroxyl-
ation with subsequent glucuronide or sulfate conjugation.
Many factors contribute to POV that were not controlled 
for such as the use of reversal agents, hydration status, etc. 
Ideally, alternative methods of anesthesia and analgesia could 
Table 1 Demographics and perioperative data of the study 
groups
 ODT  Placebo*
  (n = 35)  (n = 31)
Age (yrs)  6.1 ± 1.7  6.7 ± 2.4
Weight (kg)  24.6 ± 6.9  24.9 ± 8
Gender male (%)  51  58
ASA/I/II (%)  80/20  70/30
Duration of anesthesia (min)  77 ± 19  60 ± 17**
Received morphine (PACU)  22 (63%)  15 (48%)
Postoperative length of stay (min)  116 ± 67  127 ± 36
Notes: *Placebo controls compiled from historical data in previous studies of 
PONV; **p < 0.05 compared with ODT
Table 2 Postoperative outcomes in the study groups [n(%)]
 ODT    Placebo 
  (n = 35)  (n = 31)
POV in hospital  5 (14%)  21 (68%)**
POV in 24 hours  8 (24%)*  26 (84%)**
Rescue antiemetic in hospital  4 (11%)  17 (55%)**
Severe vomiting (3 episodes) /24 hrs  6 (18%)*  19 (61%)**
ACR  25 (76%)  5 (16%)**
Notes: *2 children lost to follow-up; **P ≤ 0.001 compared with ODT; ACR, Acute 
complete response, deﬁ  ned as no emetic episodes and no rescue medications 
within 24 hours.Therapeutics and Clinical Risk Management 2007:3(4) 694
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potentially lower the emetogenic potential in this population 
or the addition of other antiemetics such as dexamethasone 
in combination with the ODT. Ondansetron and dolasetron 
demonstrated comparative efﬁ  cacy when used in combination 
with dexamethasone for POV prophylaxis in children under-
going tonsillectomy surgery (Sukhani et al 2002). Studies 
have also shown that the combination of metoclopramide 
with ondansetron was no more effective than ondansetron 
alone in children undergoing strabismus surgery. Hence the 
addition of metoclopramide in a prophylaxis regimen for 
PONV is probably not warranted (Kathirvel et al 1999). The 
ODT offers a unique, cost effective, formulation of a 5HT3 
agent that is readily acceptable and safe in the pediatric surgi-
cal population. Additionally, while PONV is unpleasant for 
the child, it can also be disturbing to the parents and actually 
increase their time spent nursing the child in PACU. 
Limitations
One important limitation of this study is the use of historical 
controls. It was felt that the use of a placebo control – in the 
case of children undergoing a known highly emetogenic 
surgery – was unethical given the known risks. Additionally 
data obtained from previous studies within the same 
institution provided a fairly equal distribution of matched 
controls that could be used for comparison. Although faculty 
and staff performing the surgeries had changed, the use of 
research personnel to ensure compliance with the identical 
protocols was critical.
Conclusion
The ODT is a readily acceptable form of a 5HT3 antagonist 
that can be safely used in children undergoing strabismus 
surgery for the prevention of POV. Additional studies are 
warranted to evaluate its utility in other types of pediatric 
surgeries with high incidences of POV and also its effective-
ness as a rescue agent in the PACU.
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